– USA, CA – Bodyport, the digital health company focused on the detection and management of heart disease, today announced the close of an $11.2 million Series A investment round led by Boehringer Ingelheim Venture Fund alongside existing investors Playground Global and Initialized Capital, among others.…
– SWITZERLAND, Basel – T3 Pharmaceuticals AG, Swiss biotech advancing immuno-oncology with its bacteria-based protein delivery platform, today announced the closing of its third financing round, raising over 25M CHF in a round co-led by existing investors, including the Boehringer Ingelheim Venture Fund, Reference Capital, Wille Finance, as well as private investors also participating in the round.…
– USA, NY – Wellth, a platform designed to improve treatment adherence using behavioral economics, announced today that it has closed $10M in Series A funding round co-led by existing investors yabeo and Boehringer Ingelheim Venture Fund with participation from returning investors AXA Venture Partners, New York Life Ventures, NFP Ventures, I2BF Global Ventures, and Partnership Fund for New York City, and new investors Rock Health and DaVita Venture Group.…
– USA, CA – Actym Therapeutics, a privately-held immuno-oncology company, today announced the completion of a $34 million Series A financing led by Boehringer Ingelheim Venture Fund and Panacea Venture, with participation from Illumina Ventures, Korea Investment Partners, and JLo Ventures.…
– SWITZERLAND, Basel – NBE-Therapeutics AG today announces the closing of a USD 22M Series C financing round led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group and with participation from all private shareholders.…